Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action

Introduction: MDD represents a significant burden worldwide, and while a number of approved treatments exist, there are high rates of treatment resistance and refractoriness. Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist, is a novel, rapid-acting antidepressant, however the mechanism...

Full description

Bibliographic Details
Main Authors: Madison N. Irwin, PharmD, Amy VandenBerg, PharmD, BCPP
Format: Article
Language:English
Published: American Association of Psychiatric Pharmacists 2021-05-01
Series:Mental Health Clinician
Subjects:
Online Access:https://theijpt.org/doi/pdf/10.9740/mhc.2021.05.200